Efficacy and adverse events related to the initial dose of methimazole in children and adolescents with Graves’ disease
Purpose The first-line antithyroid drug for children and adolescents with Graves’ disease (GD) is methimazole (MMI). This study evaluated the relationship between the initial MMI dose and the clinical course of GD after treatment. Methods We studied the efficacy of the initial MMI dose and the relat...
Main Authors: | Hyun Gyung Lee, Eun Mi Yang, Chan Jong Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Society of Pediatric Endocrinology
2021-09-01
|
Series: | Annals of Pediatric Endocrinology & Metabolism |
Subjects: | |
Online Access: | http://e-apem.org/upload/pdf/apem-2142046-023.pdf |
Similar Items
-
Two Cases of Methimazole-Induced Insulin Autoimmune Syndrome in Graves' Disease
by: Eun Roh, et al.
Published: (2013-03-01) -
Efficacy of low-dose methimazole in control of multiple relapses of Graves’ hyperthyroidism: a case report
by: Fereidoun Azizi, et al.
Published: (2021-04-01) -
Evaluating the Role of Circulating Dendritic Cells in Methimazole-Treated Pediatric Graves’ Disease Patients
by: Aleksandra Starosz, et al.
Published: (2021-01-01) -
Insulin autoimmune syndrome induced by methimazole in a Korean girl with Graves' disease
by: Sun Hee Lee, et al.
Published: (2013-03-01) -
Predictive factors for early response to methimazole in children and adolescents with Graves disease: a single-institute study between 1993 and 2013
by: Sun Mi Hwang, et al.
Published: (2016-06-01)